Q3 Earnings Estimate for Penumbra Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised its Q3 2025 earnings per share estimate for Penumbra from $1.00 to $0.85, while the consensus estimate for the current full-year earnings stands at $3.67 per share.
• Despite the lowered earnings estimate, multiple analysts including UBS Group, Wall Street Zen, and Canaccord Genuity have maintained or raised their price targets, with a consensus price target of $300.07 for Penumbra.
• Institutional investors hold 88.88% of Penumbra's stock, with significant increases in holdings reported by firms such as Synergy Investment Management and First Horizon Advisors in recent quarters.

Penumbra, Inc. (NYSE:PEN - Free Report) - Investment analysts at Leerink Partnrs cut their Q3 2025 EPS estimates for shares of Penumbra in a research report issued on Wednesday, July 30th. Leerink Partnrs analyst M. Kratky now anticipates that the company will earn $0.85 per share for the quarter, down from their prior estimate of $1.00. The consensus estimate for Penumbra's current full-year earnings is $3.67 per share. Leerink Partnrs also issued estimates for Penumbra's Q4 2025 earnings at $1.08 EPS, FY2025 earnings at $3.63 EPS, FY2026 earnings at $5.69 EPS, FY2027 earnings at $7.43 EPS, FY2028 earnings at $8.69 EPS and FY2029 earnings at $9.82 EPS.

PEN has been the topic of a number of other research reports. Morgan Stanley increased their price target on shares of Penumbra from $260.00 to $266.00 and gave the stock an "equal weight" rating in a report on Thursday. Wells Fargo & Company reduced their target price on shares of Penumbra from $315.00 to $290.00 and set an "overweight" rating on the stock in a report on Wednesday. William Blair raised shares of Penumbra to a "strong-buy" rating in a report on Friday, July 18th. Stifel Nicolaus set a $318.00 target price on shares of Penumbra and gave the company a "buy" rating in a report on Thursday, April 24th. Finally, BTIG Research reissued a "buy" rating on shares of Penumbra in a research report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $300.47.

Penumbra Price Performance

Shares of NYSE:PEN traded down $9.77 during trading on Thursday, reaching $242.50. The company had a trading volume of 694,067 shares, compared to its average volume of 496,865. The company has a fifty day moving average of $249.42 and a two-hundred day moving average of $267.25. The stock has a market capitalization of $9.46 billion, a P/E ratio of 64.49, a price-to-earnings-growth ratio of 2.19 and a beta of 0.40. Penumbra has a 12 month low of $163.63 and a 12 month high of $310.00. The company has a current ratio of 6.75, a quick ratio of 3.68 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.05. The business had revenue of $339.46 million for the quarter, compared to analyst estimates of $327.37 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. Penumbra's revenue was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.64 EPS.

Insider Activity

In other Penumbra news, Director Bridget O'rourke sold 100 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $286.15, for a total value of $28,615.00. Following the completion of the transaction, the director directly owned 5,423 shares in the company, valued at $1,551,791.45. This represents a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Adam Elsesser sold 16,150 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $233.16, for a total transaction of $3,765,534.00. Following the completion of the transaction, the chief executive officer owned 146,258 shares of the company's stock, valued at approximately $34,101,515.28. The trade was a 9.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 115,735 shares of company stock valued at $30,476,510 in the last 90 days. Company insiders own 4.20% of the company's stock.

Hedge Funds Weigh In On Penumbra

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Quadrant Capital Group LLC boosted its position in shares of Penumbra by 6.6% during the fourth quarter. Quadrant Capital Group LLC now owns 632 shares of the company's stock worth $150,000 after acquiring an additional 39 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Penumbra by 7.3% during the second quarter. GAMMA Investing LLC now owns 761 shares of the company's stock worth $195,000 after acquiring an additional 52 shares during the last quarter. Baker Avenue Asset Management LP lifted its position in Penumbra by 1.6% during the fourth quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company's stock valued at $791,000 after purchasing an additional 53 shares during the last quarter. Fifth Third Bancorp lifted its position in Penumbra by 16.4% during the first quarter. Fifth Third Bancorp now owns 404 shares of the company's stock valued at $108,000 after purchasing an additional 57 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its position in Penumbra by 404.8% during the first quarter. First Horizon Advisors Inc. now owns 106 shares of the company's stock valued at $28,000 after purchasing an additional 85 shares during the last quarter. Institutional investors own 88.88% of the company's stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.